TSE:4502Pharmaceuticals
Takeda Takes Full U.S. Rusfertide Rights Sharpening Rare Disease Focus
Takeda Pharmaceutical (TSE:4502) has secured exclusive U.S. development and commercialization rights to rusfertide.
The change follows Protagonist Therapeutics' decision to opt out of the collaboration.
Rusfertide is currently under FDA Priority Review in the U.S.
For investors watching Takeda, this move centers attention on its rare disease pipeline and its broader focus on specialty medicines. By taking full U.S. control of rusfertide, Takeda aligns the asset with its existing...